The Role of Arginine for Treating Obese Youth

Global Perspectives on Childhood Obesity

Volumn , Issue , 2011, Pages 433-441

  McNeal, Catherine J ^a   Wu, Guoyao ^b   Vasquez, Susie ^a   Wilson, Don P ^c   Satterfield, M Carey ^b   McKnight, Jason R ^b   Malbari, Hussain S ^a   Rahman, Mujtaba ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c PHOENIX CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882825267     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374995-6.10040-4     Document Type: Chapter

References (60)

1. Olshansky S.J., Passaro D.J., Hershow R.C., Layden J., Carnes B.A., Brody J., Hayflick L., Butler R.N., Allison D.B., Ludwig D.S. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138-1145.
2. Mokdad A.H., Marks J.S., Stroup D.F., Gerberding J.L. Actual causes of death in the United States, 2000. JAMA 2004, 291:1238-1245.
3. Hill J.O., Wyatt H.R., Reed G.W., Peters J.C. Obesity and the environment: where do we go from here?. Science 2003, 299:853-855.
4. Abelson P., Kennedy D. The obesity epidemic. Science 2004, 304:1413.
5. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
6. Williams C.L., Gulli M.T., Deckelbaum R.J. Prevention and treatment of childhood obesity. Atheroscler Rep 2001, 3:486-497.
7. Ogden C.L., Carroll M.D., Flegal K.M. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 2003, 32:741-760.
8. Bell A.C., Ge K., Popkin B.M. Weight gain and its predictors in Chinese adults. Int J Obes 2001, 25:1079-1086.
9. Pi-Sunyer X. A clinical view of the obesity problem. Science 2003, 299:859-860.
10. Finkelstein EA, Fiebelkorn IC, Wang G. (2003). National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood) Suppl Web Exclusives: W3-219-26.
11. US Preventive Services Task Force Screening and interventions for overweight in children and adolescents: recommendation statement. Pediatrics 2005, 116:205-209.
12. Monzavi R., Dreimane D., Geffner M.E., Braun S., Conrad B., Klier M., Kaufman F.R. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics 2006, 117:e1111-e1118.
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, and Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
14. Chanoine J.P., Hampl S., Jensen C., Boldrin M., Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293:2873-2883.
15. McDuffie J.R., Calis K.A., Booth S.L., Uwaifo G.I., Yanovski J.A. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002, 22:814-822.
16. Maahs D., de Serna D.G., Kolotkin R.L., Ralston S., Sandate J., Qualls C., Schade D.S., Ozkan B., Bereket A., Turan S., Keskin S. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004, 163:738-741.
17. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, Perry AC, Sothern MS, Renz CL, Pirner MA, Walch JK, Jasinsky O, Hewkin AC, and Blakesley VA. Sibutramine Adolescent Study Group. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145:81-90.
18. Godoy-Matos A., Carraro L., Vieira A., Oliveira J., Guedes E.P., Mattos L., Rangel C., Moreira R.O., Coutinho W., Appolinario J.C. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005, 90:1460-1465.
19. Wu G., Bazer F.W., Davis T.A., Kim S.W., Li P., Rhoads J.M., Satterfield M.C., Smith S.B., Spencer T.E., Yin Y.L. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009, 37:153-168.
20. Castillo L., deRojas T.C., Chapman T.E., Vogt J., Burke J.F., Tannenbaum S.R., Young V.R. Splanchnic metabolism of dietary arginine in relation to nitric oxide synthesis in normal adult man. Proc Natl Acad Sci USA 1993, 90:193-197.
21. Wu G., Meininger C.J. Arginine nutrition and cardiovascular function. J Nutr 2000, 130:2626-2629.
22. Boger R.H., Bode-Boger S.M. The Clinical Pharmacology of L-Arginine. Annu Rev Pharmacol Toxicol 2001, 41:79-99.
23. Yongyi B., Sun L., Yang T., Sun K., Chen J., Hui R. Increase in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2009, 89:77-84.
24. Borucki K., Aronica S., Starke I., Luley C., Westphal S. Addition of 2.5g L-arginine in a fatty meal prevents the lipemia-induced endothelial dysfunction in healthy volunteers. Atherosclerosis 2009, 205:251-254.
25. Maxwell A.J., Cooke J.P. L-Arginine: its role in cardiovascular function. "Nitric Oxide and the Cardiovascular System" 2001, 547-585. Humana, Totowa, NJ. J. Loscalzo, J.A. Vita (Eds.).
26. Lucotti P., Setola E., Monti L.D., Galluccio E., Costa S., Sandoli E.P., Fremo I., Rabaiotti G., Gatti R., Piatti P. Beneficial effects of a long-term oral L-arginine added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol 2006, 291:E906-E912.
27. Jobgen W.J., Meininger C.J., Jobgen S.C., Li P., Lee M.J., Smith S.B., Spencer T.E., Fried S.K., Wu G. Dietary L-arginine supplementation reduces white-fat gain and enhances skeletal muscle and brown fat masses in diet-induced obese rats. J Nutr 2009, 139:230-237.
28. Schulman S.P., Becker L.C., Kass D.A., Champion H.C., Terrin M.L., Forman S., Ernst K.V., Kelemen M.D., Townsend S.N., Capriotti A., Hare J.M., Gerstenblith G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006, 295:58-64.
29. Abumrad N.N., Barbul A. Arginine therapy for acute myocardial infarction. JAMA 2006, 295:2138-2139.
30. Maxwell A.J., Cooke J.P. L-Arginine: its role in cardiovascular function. "Nitric Oxide and the Cardiovascular System" 2001, 547-585. Humana, Totowa, NJ. J. Loscalzo, J.A. Vita (Eds.).
31. Lim D.S., Mooradian S.J., Goldberg C.S., Gomez C., Crowley D.C., Rocchini A.P., Charpie J.R. Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. Am J Cardiol 2004, 94:828-831.
32. Bennett-Richards K.J., Kattenhorn M., Donald A.E., Oakley G.R., Varghese Z., Bruckdorfer K.R., Deanfield J.E., Rees L. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002, 62:1372-1378.
33. Amin H.J., Zamora S.A., McMillan D.D., Fick G.H., Butzner J.D., Parsons H.G., Scott R.B. Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J Pediatr 2002, 140:425-431.
34. Fu W.J., Haynes T.E., Kohli R., Hu J., Shi W., Spencer T.E., Carroll R.J., Meininger C.J., Wu G. Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr 2005, 135:714-721.
35. Wu G., Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochem J 1998, 336:1-17.
36. Morris S.M. Recent advances in arginine metabolism. Curr Opin Clin Nutr Metab Care 2004, 7:45-51.
37. Kohli R., Meininger C.J., Haynes T.E., Yan W., Self J.T., Wu G. Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J Nutr 2004, 134:600-608.
38. Wu Z.D., Puigserver P., Andersson U., Zhang C.Y., Adelmant G., Mootha V., Troy A., Cinti S., Lowell B., Scarpulla R.C., Spiegelman B.M. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
39. Lehman J.J., Barger P.M., Kovacs A., Saffitz J.E., Medeiros D.M., Kelly D.P. Peroxisome proliferator-activated receptor γ co-activator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000, 106:847-856.
40. Nisoli E., Clementi E., Paolucci C., Cozzi V., Tonello C., Sciorati C., Bracale R., Valerio A., Francolini M., Moncada S., Carruba M.O. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003, 299:896-899.
41. ω-nitroarginine. Biosci Biotech Biochem 1999, 63:698-702.
42. Gaudiot N., Jaubert A.M., Charbonnier E., Sabourault D., Lacasa D., Giudicelli Y., Ribiere C. Modulation of white adipose tissue lipolysis by nitric oxide. J Biol Chem 1998, 273:13475-13481.
43. Lincova D., Misekova D., Kmonickova E., Canova N., Farghali H. Effect of nitric oxide donors on isoprenaline-induced lipolysis in rat epididymal adipose tissue: studies in isolated adipose tissues and immobilized perfused adipocytes. Physiol Res 2002, 51:387-394.
44. ω-nitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation. J Nutr 1996, 126:2563-2567.
45. Kurowska E.M., Carroll K.K. Hypochelesterolemic properties of nitric oxide: in vivo and in vitro studies using nitric oxide donors. Biochim Biophys Acta 1998, 1392:41-50.
46. Gaudiot N., Ribiere C., Jaubert A.M., Giudicelli Y. Endogenous nitric oxide is implicated in the regulation of lipolysis through antioxidant-related effect. Am J Physiol 2000, 279:C1603-C1610.
47. Fruhbeck G., Gomez-Ambrosi G. Modulation of the leptin-induced white adipose tissue liposis by nitric oxide. Cell Signal 2001, 13:827-833.
48. Tan B.E., Yin Y.L., Liu Z.Q., Li X.G., Xu H.J., Kong X.F., Huang R.L., Tang W.J., Shinzato I., Smith S.B., Wu G. Dietary L-arginine supplementation increases muscle gain and reduces body fat mass in growing-finishing pigs. Amino Acids 2009, 37:169-175.
49. He Q.H., Kong X.F., Wu G., Ren P.P., Tang H.R., Hao F.H., Huang R.L., Li T.J., Tan B.E., Li P., Tang Z.R., Yin Y.L., Wu Y.N. Metabolomic analysis of the response of growing pigs to dietary L-arginine supplementation. Amino Acids 2009, 37:199-208.
50. Meininger C.J., Cai S., Parker J.L., Channon K.M., Kelly K.A., Becker E.J., Wood M.K., Wu G. GTP cyclohydrolase I gene transfer increases nitric oxide synthesis in endothelial cells and isolated vessels from type I and type II diabetic rats. FASEB J 2004, 18:1900-1902.
51. Clark J., Palmer C.J., Shaw W.N. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983, 173:68-75.
52. Lee WNP, Bassilian S, Lim S, and Boros LG. Loss of regulation of lipogenesis in the Zucker diabetic fatty (ZDF) rat. Am J Physiol 2000;279:E425-E432.
53. Hardie D.G., Pan D.A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002, 30:1064-1070.
54. Tomas E., Kelly M., Xiang X.Q., Tsao T.S., Keller C., Keller P., Luo Z.J., Lodish H., Saha A.K., Unger R., Ruderman N.B. Metabolic and hormonal interactions between muscle and adipose tissue. Proc Nutr Soc 2004, 63:381-385.
55. Garcia-Villafranca J., Guillen A., Castro J. Involvement of nitric oxide/cyclic GMP signaling pathway in the regulation of fatty acid metabolism in rat hepatocytes. Biochem Pharmacol 2003, 65:807-812.
56. Jobgen W., Fu W.J., Gao H., Li P., Meininger C.J., Smith S.B., Spencer T.E., Wu G. High fat feeding and dietary L-arginine supplementation differentially regulate gene expression in rat white adipose tissue. Amino Acids 2009, 37:187-198.
57. Wu G., Meininger C.J. Nitric oxide and vascular insulin resistance. BioFactors 2009, 35:21-27.
58. Wu G., Lee M.J., Fried S.K. The arginine-NO pathway modulates lipolysis in adipose tissues of obese human subjects. FASAB J 2007, 21:A1052.
59. Trujillo M.E., Sullivan S., Harten I., Schneider S.H., Greenberg A.S., Fried S.K. Interleukin-6 Regulates Human Adipose Tissue Lipid Metabolism and Leptin Production in vitro. JCEM 2004, 89:5577-5582.
60. Jobgen W.S., Fried S.K., Fu W.J., Meininger C.J., Wu G. Regulatory role for the arginine-nitric oxide pathway in energy-substrate metabolism. J Nutr Biochem 2006, 17:571-588.